Overview

A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, open-label, parallel group, study being conducted in the United States and in Europe in postmenopausal women. Approximately 800 subjects will be randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or ibandronate 150mg PO QM.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Denosumab
Diphosphonates
Ibandronic Acid